ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Johnson Matthey Buys Biocatalysis Company

by Michael McCoy
July 12, 2010 | APPEARED IN VOLUME 88, ISSUE 28

Johnson Matthey has acquired X-Zyme, a Düsseldorf, Germany-based provider of enzymes, particularly oxidoreductases, and chiral intermediates. X-Zyme is a 2001 spin-off from Heinrich Heine University’s Institute of Molecular Enzyme Technology. It will become part of Johnson Matthey’s catalysis and chiral technologies business, established to provide catalysis to the pharmaceutical, fine chemicals, and agrochemical markets. More than 20% of pharmaceutical intermediates contain chiral alcohols, according to Johnson Matthey.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment